HC Wainwright & Co. initiated coverage on PharmaCyte Biotech

11/8/21 6:05:27 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PMCB

Date	Price Target	Rating	Analyst
11/8/2021		Neutral	HC Wainwright & Co.